Page 240 - 2021_05-Haematologica-web

1460
Letters to the Editor
Pamplona, Spain; 4CIBER-ONC (CB16/12/00369), Pamplona, Spain; 5CIBER-ONC (CB16/12/00489), Pamplona, Spain; 6Clinica Universidad de Navarra, Madrid, Spain; 7Hospital “Annunziata”, Cosenza, Italy; 8Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 9Centro de Sangue e Transplantação de Coimbra, Instituto Português do Sangue e da Transplantação, Coimbra, Portugal and 10Hospital Universitario Central de Asturias, Oviedo, Spain
*CM, EM-S, JJG and AL-DC contributed equally as co-first authors. #BP and JRY contributed equally as co-senior authors.
Correspondence:
JOSE’ RAMON YUSTE - jryuste@unav.es
doi:10.3324/haematol.2020.269878 Received: August 14, 2020.
Accepted: December 4, 2020. Pre-published: December 17, 2020. Disclosures: no conflicts of interest to disclose.
Contributions: BP and JRY conceived the idea and designed the study protocol; ALDdC, SI, CP, and LB performed flow cytometry immunophenotyping; CMa, EMS, ALDdC, SI, CP, AZ, CMo, and BP analyzed flow cytometry data; CP and DA performed cell sorting; SS and AV-Z performed next-generation RNA sequencing;
JJG analyzed RNAseq data. MFL, BGA, FA, CR, AP, AM, RA, EC, CQ, MO, AB, JA and JRY provided study material and/or patients; CMa, EMS, JJG, CP, CB and BP performed statistical analysis; CMa, EMS, JJG, BP and JRY wrote the manuscript.
Acknowledgments: the authors would like to acknowledge Astrid Cuellar, Andrea Jimenez and Jaione Larraiotz for outstanding performance of flow cytometry immunophenotyping.
Funding: this study was supported by the Centro de Investigación Biomédica en Red – Área de Oncología - del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369 and CB16/12/00489), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI17/01243), Fondo Europeo de Desarrollo Regional (FEDER), Fundación BBVA, Departamento de Salud de Gobierno de Navarra, Departamento de Salud de Gobierno de Navarra (0011-3638-2020-000004)and Asociación Española Contra el Cáncer (FCAECC, Predoctoral Grant Junta Provincial Navarra). This study was supported internationally by the Cancer Research UK, FCAECC and AIRC under the Accelerator Award Program, Black Swan Research Initiative of the International Myeloma Foundation,
the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT), the MMRF Immunotherapy Networks of Excellence and the 2017 European Hematology Association (EHA) non-clinical advanced research grant (3680644).
References
1. Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK. The COVID-19 and Cancer Consortium: a collaborative effort to understand the effects of COVID-19 on patients with cancer. Cancer Cell. 2020;37(6):738-741.
2. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulner- able to SARS-CoV-2: a multicenter study during the COVID-19 out- break. Cancer Discov. 2020;10(6):783-791.
3. Robilotti E V., Babady NE, Mead PA, et al. Determinants of COVID- 19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-1223.
4. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King’s College Hospital experience. Br J Haematol. 2020;190(5):e279-e282.
5. He W, Chen L, Chen L, et al. COVID-19 in persons with haemato- logical cancers. Leukemia. 2020;34(6):1637-1645.
6. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Leukemia. 2020; 34(7):1954-1956.
7. Gonzalez-Lugo JD, Bachier-Rodriguez L, Goldfinger M, et al. A case series of monoclonal gammopathy of undetermined significance and COVID-19. Br J Haematol. 2020;190(3):e130-e133.
8. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7):834-847.
9. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. Br J Haematol. 2020;190(5):e279-e282.
10. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915.
11. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910-941.
12. Witkowski MT, Dolgalev I, Evensen NA, et al. Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia. Cancer Cell. 2020;37(6):867-882.
13. Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98(1):79-86.
14. Criado I, Blanco E, Rodríguez-Caballero A, et al. Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia. 2018;32(12):2701-2705.
haematologica | 2021; 106(5)